Expert Ratings for Belite Bio
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 Wall Street analysts have consistently given Belite Bio (NASDAQ:BLTE) a bullish rating. The average 12-month price target for BLTE is $58.75, with a high of $60.00 and a low of $57.00, marking a 6.82% increase from the previous target of $55.00. Analysts' ratings are based on research, financial statements, and insider information, and are updated typically once a quarter.
December 14, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio received a unanimous bullish rating from 4 Wall Street analysts over the past 3 months, with an updated average price target of $58.75, indicating a positive sentiment and potential upside from the previous target of $55.00.
The unanimous bullish rating from analysts and the increase in the average price target are strong indicators of positive sentiment towards BLTE. This consensus could lead to increased investor confidence and a potential short-term rise in the stock price. However, as analyst ratings are opinions, the actual market performance will depend on various factors including market conditions and company performance.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100